Results 161 to 170 of about 74,157 (302)

Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease

Rheumatology &Autoimmunity, EarlyView.
Sera from patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease (ILD) exhibit significantly higher type I interferon (IFN‐I) bioactivity and interferon‐stimulated gene‐inducing activity compared to anti‐ARS‐positive ILD and healthy controls.
Shohei Nakamura, Yasuhiro Katsumata, Yuko Okamoto, Masayoshi Harigai   +3 more
wiley   +1 more source

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

Respirology, EarlyView.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

Janus Kinase Inhibitors and Body Weight: Current Evidence and Potential. [PDF]

Life (Basel)
Kraev K, Basheva-Kraeva Y, Uchikova M, Uchikov P, Hristov B, Valova S, Doykov M, Stanchev D, Boyukliev A, Batalov Z.   +9 more
europepmc   +1 more source

Modeling the lung‒brain axis in critical illness: Multifactorial crosstalk through organoids and organ‐on‐a‐chip system

VIEW, EarlyView.
Patients in intensive care units often experience lung injuries, complicated by brain problems. Advanced laboratory tools, organoids, and organs‐on‐chips facilitated the study of multiorgan interactions, help us understand the communication between the lungs and brain.
Wanyi Zhang, Ting Wang, Mengying Yao, Longxiang Su, Lixin Xie, Pan Pan   +5 more
wiley   +1 more source

Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. [PDF]

World J Gastrointest Pharmacol Ther
Malakar S, Giri S, Jena A, Nath P.
europepmc   +1 more source

Sphinganine‐phosphate prevents influenza infection via promoting CD8+ T cells proliferation and activation

VIEW, EarlyView.
This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...
Zhongwen Hu, Guiling Yan, Junhong Li, Yuan Yuan, Hong Zhang, Yuchao Zhong, Yuanyuan Peng, Wenjia Zhang, Xiaoyan Su, Changchun Niu, Yang Luo   +10 more
wiley   +1 more source

Janus kinase inhibitors in giant cell arteritis: unmet needs and new challenges. [PDF]

Reumatologia
Gkouvi A, Patrikiou E, Grammatikopoulou MG, Bogdanos DP.   +3 more
europepmc   +1 more source

Tapinarof as a Therapeutic Aryl Hydrocarbon Receptor‐Modulating Agent in the Treatment of Atopic Dermatitis

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory dermatitis underpinned by Type 2 inflammation driven by cytokines such as IL‐4 and IL‐13. It is characterized by skin barrier dysfunction, Th2 immune deviation, and pruritus. While biologics and oral Janus kinase (JAK) inhibitors demonstrate high therapeutic efficacy by targeting cytokines that ...
Gaku Tsuji, Yoko Fuyuno, Koji Kawamura, Ayako Yumine, Masaki Takemura, Yasutaka Mitamura, Kazuhiko Yamamura, Takeshi Nakahara   +7 more
wiley   +1 more source

Emerging role of Janus kinase inhibitors in ulcerative colitis management. [PDF]

World J Gastrointest Pharmacol Ther
Ahsan MU, Sajid SL, Balach R, Daniyal M, Ain NU, Mudasir M.   +5 more
europepmc   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source